Sensorion SA (PA:ALSEN) — Market Cap & Net Worth
Market Cap & Net Worth: Sensorion SA (ALSEN)
Sensorion SA (PA:ALSEN) has a market capitalization of $122.13 Million (€104.47 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #18527 globally and #268 in its home market, demonstrating a 3851.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sensorion SA's stock price €9.19 by its total outstanding shares 515334604 (515.33 Million). Also see Sensorion SA total assets for a full breakdown of the balance sheet.
Sensorion SA Market Cap History: 2015 to 2026
Sensorion SA's market capitalization history from 2015 to 2026. Data shows change from $5.25 Billion to $5.53 Billion (-2.80% CAGR). Also see cash flow conversion of Sensorion SA for how efficiently the company converts equity into cash flow.
Sensorion SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sensorion SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALSEN stock price and chart for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
57.59x
Sensorion SA's market cap is 57.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $2.90 Billion | $17.50K | -$7.41 Million | 165596.02x | N/A |
| 2017 | $2.23 Billion | $1.93 Million | -$9.69 Million | 1152.36x | N/A |
| 2018 | $606.10 Million | $2.23 Million | -$12.35 Million | 271.74x | N/A |
| 2019 | $509.10 Million | $2.46 Million | -$12.10 Million | 207.23x | N/A |
| 2020 | $903.72 Million | $2.35 Million | -$8.98 Million | 384.22x | N/A |
| 2021 | $1.16 Billion | $4.26 Million | -$15.14 Million | 272.15x | N/A |
| 2022 | $222.92 Million | $4.93 Million | -$23.21 Million | 45.18x | N/A |
| 2023 | $259.07 Million | $5.70 Million | -$22.06 Million | 45.47x | N/A |
| 2024 | $383.18 Million | $6.65 Million | -$25.97 Million | 57.59x | N/A |
Competitor Companies of ALSEN by Market Capitalization
Companies near Sensorion SA in the global market cap rankings as of September 20, 2026. Review Sensorion SA (ALSEN) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Sensorion SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Sensorion SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Sensorion SA's market cap moved from $5.25 Billion to $ 5.53 Billion, with a yearly change of -2.80%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €5.53 Billion | +2626.11% |
| 2025 | €203.04 Million | -47.01% |
| 2024 | €383.18 Million | +47.91% |
| 2023 | €259.07 Million | +16.22% |
| 2022 | €222.92 Million | -80.79% |
| 2021 | €1.16 Billion | +28.40% |
| 2020 | €903.72 Million | +77.51% |
| 2019 | €509.10 Million | -16.00% |
| 2018 | €606.10 Million | -72.81% |
| 2017 | €2.23 Billion | -23.08% |
| 2016 | €2.90 Billion | -44.84% |
| 2015 | €5.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Sensorion SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $122.13 Million USD |
| MoneyControl | $122.13 Million USD |
| MarketWatch | $122.13 Million USD |
| marketcap.company | $122.13 Million USD |
| Reuters | $122.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sensorion SA
Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutat… Read more